TWO BE studies ENRICH and ENHANCE of TSCB (02137) for the treatment of chronic hepatitis B announced the top-line data at the end of the treatment.

Zhtng Cijng APP Xn, tng shng b yo -B (02137) fb gnggo, bn gngs zhngzi jnxng de 2b q ENRICH j ENHANCE ynji de zhlio jish sh (EOT) jigu. Shngsh ynji zhzi pngg BRII-179 y elebsiran j p y r j tngsu fn' (PEG-IFN) zi mnzhng yxng hpngbng do ynghn de xsun y tngb linh zhlio fng'n. Zhtng Cijng APP News, Tengshengbo Medicine-B (02137) announced that the company is releasing the end-of-treatment (EOT) results of the ongoing 2b phase ENRICH and ENHANCE studies. The above studies aim to evaluate the sequential and simultaneous combination treatment of BRII-179 with elebsiran and pegylated interferon (PEG-IFN) in chronic hepatitis B virus (HBV) infection.